[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626889":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":42,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":10,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Tianjin Medical University Second Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Study group",null,[12],"Diagnostic Test: Multi-Component Liquid Biopsy for Urothelial Carcinoma",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Multi-Component Liquid Biopsy for Urothelial Carcinoma","This intervention is a non-invasive, multi-component liquid biopsy assay specifically designed for patients with urothelial carcinoma (including bladder cancer and upper tract urothelial carcinoma). It integrates multiple tumor-derived analytes from paired blood and urine samples: circulating cell-free DNA (cfDNA)\u002Fcirculating tumor DNA (ctDNA) from peripheral blood plasma, urinary tumor DNA (utDNA)\u002Fcell-free DNA from urine, exosomal RNAs (e.g., miRNAs, lncRNAs) and proteins from urine-derived exosomes, and selected tumor-associated proteins.\n\nSerial sampling is performed at key clinical time points to enable longitudinal assessment:\n\n1. Pre-diagnosis or baseline\n2. During treatment\n3. Post-treatment surveillance",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Hailong Hu, MD","CONTACT","+8613662096232","huhailong@tmu.edu.cn",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"The second hospital of Tianjin Medical University","RECRUITING","Tianjin","300000","China","CN",{"type":34,"coordinates":35},"Point",[36,37],117.17667,39.14222,{"lat":37,"lon":36},[40],{"name":41,"role":22,"phone":23,"phoneExt":10,"email":24},"Hailong Hu",{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100626889","using-liquid-biopsy-testing-to-identify-monitor-predict-recurrence-in-urothelial-carcinoma-100626889",false,"NCT07441499","Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma","Inclusion Criteria:\n\n* Suspected or histologically confirmed urothelial carcinoma\n\nExclusion Criteria:\n\n* History of or concurrent active malignancy other than urothelial carcinoma","ALL","18 Years",{"count":53,"type":54},300,"ESTIMATED","OBSERVATIONAL","Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma",[58,59,60],"Urothelial Carcinoma (UC)","Bladder (Urothelial, Transitional Cell) Cancer","Liquid Biopsy","2026-02-27",{"date":63,"type":64},"2026-03-02","ACTUAL",{"date":66,"type":54},"2026-03",{"date":68,"type":54},"2029-01-01",{"name":5,"class":6},1]